Planfoy

Researchers are evaluating the effectiveness of early erectile rehabilitation using Sildenafil in men who have undergone neoadjuvant radiotherapy followed by proctectomy for rectal cancer. Erectile dysfunction is a common complication after these treatments due to nerve damage and vascular injury, significantly impacting quality of life. This phase 3 study aims to prevent long-term erectile dysfunction by starting treatment 30 days after surgery and continuing for 10 months. Participants are randomly assigned to receive either Sildenafil (50 mg daily) or a placebo, both started 30 days after surgery and taken daily for 10 months. The study compares these two groups to assess whether Sildenafil can help maintain erectile function postoperatively. The treatment aims to promote nocturnal erections to oxygenate erectile tissue and prevent fibrosis, which can cause permanent dysfunction. Throughout the study, researchers will monitor participants for erectile function response at 12 months after surgery. Assessments include regular evaluations of sexual activity and function, ensuring patients meet criteria such as having a regular sexual partner and normal preoperative erectile function. Safety and adherence to treatment are tracked, with follow-up extending over a year to measure long-term outcomes and any adverse effects.